Dosing and Administration
Self-administered Hizentra lets you plan treatment around your patient's life
Your patients are all different and deserve a treatment with the flexibility to fit their individual needs and preferences. Use the guidelines and dosing calculator below to initiate a patient's Hizentra therapy. Monitor the patient's clinical response and adjust the duration of therapy based on patient need.
See how easy self-administration is with Hizentra
Watch a video that provides step-by-step instructions to
help patients infuse Hizentra.
Free online administration training is available for CIDP
Become a SHARE Hizentra administration specialist:
- Complete training in about 1 hour at your convenience
- Get a certificate of completion
- Add your practice to the Nurse Locator so patients in your area can find you!
Convenient dosing and self-administration for CIDP
Administration volumes and rates for Hizentra (as tolerated)
|
Infusion parameters* |
1st infusion |
Subsequent infusions |
|---|---|---|---|
| Volume (mL/site) | ≤20 | ≤50 | |
| Rate (mL/hr/site) | ≤20 | ≤50 | |
CIDP dosing calculator
To see number of vials, select vial size:
Number of vials: XXX
Formula used to calculate the weekly dose in mL from the patient's weight in kg:
For 0.2 g/kg dose (1:1 ratio)
| Patient weight in kg = Weekly dose in mL Example: 80 kg weight = Weekly dose of 80 mL |
For 0.4 g/kg dose (1:2 ratio)
| Patient weight in kg x 2 = Weekly dose in mL Example: 80 kg weight = Weekly dose of 160 mL |
Formula used to convert the weekly dose in mL to g:
|
Weekly dose in mL
5 |
= | Weekly dose in g |
| Example: 80 mL = 16 g | ||
Initiate therapy 1 week after last IVIg infusion
-
Recommended subcutaneous dose is 0.2g/kg (1 mL/kg) body weight (bw) per week
- During PATH, both 0.2 g/kg and 0.4 g/kg doses were found to be safe and effective. Patients who relapsed were restabilized with IVIg
- During the OLE study to PATH, patients who relapsed on 0.2 g/kg were titrated to 0.4 g/kg without IVIg restabilization
Proactively monitor and optimize therapy
- Monitor the patient's clinical response and adjust the duration of therapy based on patient need
- Volume and rate can be adjusted after initial infusion as tolerated, which may decrease infusion time and number of sites
- Consider changing one variable at time (eg, rate, volume, ancillary supplies, site) to continue tailoring treatment for your patient
- Hizentra may be infused in up to 8 infusion sites simultaneously, depending on volume
Administering Hizentra therapy
Hizentra should be administered subcutaneously only. Do not administer intravenously. Hizentra can be administered weekly for CIDP in 1 or 2 sessions over 1 or 2 consecutive days, using an infusion pump and relatively small needle(s).
- A Hizentra dose may be infused into multiple injection sites. Use up to 8 sites per infusion. More than one infusion device can be used simultaneously. Infusion sites should be at least 2 inches apart. Change the actual site of infusion with each administration
- Recommended infusion sites include the abdomen, thighs, upper arms, or side of upper leg/hip
- SC needles are smaller than IV needles. Depending on a patient's size and weight, a needle as short as 4 mm or as long as 14 mm can be used
Encourage patients to start and stay on therapy
Information and resources are available to help patients manage their ongoing administration of Hizentra.
Managing therapyFrequently asked questions about Hizentra
Want to know more about Hizentra? See answers to prescribers' frequently asked questions.
See the answers